Scinai Immunotherapeutics (SCNI) Assets Average (2020 - 2026)

Scinai Immunotherapeutics (SCNI) has 7 years of Assets Average data on file, last reported at $14.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average changed N/A year-over-year to $14.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.6 million (changed N/A YoY), and the FY2025 full-year result was $12.5 million, down 18.91% from the prior year.
• Assets Average grew to $14.6 million in Q1 2026, from $11.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $25.2 million in Q1 2023 to a low of $11.7 million in Q4 2025.
• A 5-year average of $18.1 million and a median of $17.6 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 31.45% in 2024 and slipped 8.72% in 2025, its largest moves.
• Tracing SCNI's Assets Average over 5 years: stood at $24.1 million in 2022, then declined by 25.13% to $18.0 million in 2023, then decreased by 28.69% to $12.9 million in 2024, then fell by 8.72% to $11.7 million in 2025, then gained by 24.5% to $14.6 million in 2026.
• Business Quant data shows SCNI's Assets Average at $14.6 million in Q1 2026, $11.7 million in Q4 2025, and $12.9 million in Q4 2024.